Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Drug: Melphalan flufenamide and dexamethasone for relapsed and refractory myeloma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Drug: Melphalan flufenamide and dexamethasone for relapsed and refractory myeloma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Melphalan flufenamide and dexamethasone for relapsed and refractory myeloma

New Drug: Melphalan flufenamide and dexamethasone for relapsed and refractory myeloma
Study:
  • Single-arm, phase II trial (HORIZON)
  • Multiple myeloma with >2 prior lines (including IMiD and proteasome inhibitor) and refractory to pomalidomide and/or anti-CD38 Ab
  • Monthly melflufen + weekly dexamethasone until progression (N=157)
Efficacy:
  • ORR: 29% [22% – 37%]. In triple-class refractory: 26% [18%-35%]
  • Median PFS: 4.2 mos [3.4-4.9 mos]
  • Median OS: 11.6 mos [9.3-15.4 mos]
Safety:
  • Grade >=3 AEs: neutropenia (79%), febrile neutropenia (14% vs. 9%), thrombocytopenia (76%), pneumonia (10%), nausea (<1%)

J Clin Oncol. 2020;39:757

Richardson PG, et al. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

https://doi.org/10.1200/JCO.20.02259

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More